

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8357408

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
VENTUREMED GROUP, INC.		12/21/2023
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	ENDEAVOUR MEDTECH GROWTH LP	
<b>Street Address:</b>	1 ROYAL PLAZA, ROYAL AVENUE	
<b>City:</b>	ST. PETER PORT	
<b>State/Country:</b>	GUERNSEY	
<b>Postal Code:</b>	GY1 2HL	
<b>Name:</b>	RIVERVEST VENTURE FUND III, L.P.	
<b>Street Address:</b>	11000 CEDAR AVENUE	
<b>City:</b>	CLEVELAND	
<b>State/Country:</b>	OHIO	
<b>Postal Code:</b>	44106	
<b>Name:</b>	RIVERVEST VENTURE FUND III (OHIO), L.P.	
<b>Street Address:</b>	11000 CEDAR AVENUE	
<b>City:</b>	CLEVELAND	
<b>State/Country:</b>	OHIO	
<b>Postal Code:</b>	44106	
<b>PROPERTY NUMBERS Total: 25</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	17317999	
<b>Application Number:</b>	16797585	
<b>Application Number:</b>	17886605	
<b>Application Number:</b>	17886824	
<b>Application Number:</b>	17728214	
<b>Application Number:</b>	17221473	
<b>Application Number:</b>	17221539	
<b>Application Number:</b>	17856435	
<b>Application Number:</b>	17702336	
<b>Application Number:</b>	17702344	

Property Type	Number
Application Number:	14993478
Application Number:	14991493
Application Number:	13613914
Application Number:	14990883
Application Number:	15481552
Application Number:	15200767
Application Number:	15368604
Application Number:	15441398
Application Number:	15481562
Application Number:	15861955
Application Number:	15861969
Application Number:	16673338
Application Number:	16693521
Application Number:	16693520
Application Number:	16801809

#### CORRESPONDENCE DATA

**Fax Number:** (202)799-5000

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2027994000

**Email:** gregory.esau@dlapiper.com

**Correspondent Name:** GREGORY ESAU

**Address Line 1:** 500 EIGHTH STREET, NW

**Address Line 4:** WASHINGTON, D.C. 20004

<b>NAME OF SUBMITTER:</b>	GREGORY ESAU
<b>SIGNATURE:</b>	/Gregory Esau/
<b>DATE SIGNED:</b>	01/02/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).

#### Total Attachments: 17

source=VMG - 2nd A&R IP Security Agreement#page1.tif

source=VMG - 2nd A&R IP Security Agreement#page2.tif

source=VMG - 2nd A&R IP Security Agreement#page3.tif

source=VMG - 2nd A&R IP Security Agreement#page4.tif

source=VMG - 2nd A&R IP Security Agreement#page5.tif

source=VMG - 2nd A&R IP Security Agreement#page6.tif

source=VMG - 2nd A&R IP Security Agreement#page7.tif

source=VMG - 2nd A&R IP Security Agreement#page8.tif

source=VMG - 2nd A&R IP Security Agreement#page9.tif

source=VMG - 2nd A&R IP Security Agreement#page10.tif

source=VMG - 2nd A&R IP Security Agreement#page11.tif

source=VMG - 2nd A&R IP Security Agreement#page12.tif  
source=VMG - 2nd A&R IP Security Agreement#page13.tif  
source=VMG - 2nd A&R IP Security Agreement#page14.tif  
source=VMG - 2nd A&R IP Security Agreement#page15.tif  
source=VMG - 2nd A&R IP Security Agreement#page16.tif  
source=VMG - 2nd A&R IP Security Agreement#page17.tif

## SECOND AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **Second Amended and Restated Intellectual Property Security Agreement** (as amended, modified, or otherwise supplemented from time to time, this “**Agreement**”) is executed on December 21, 2023 by VentureMed Group, Inc., a Delaware corporation (together with its successors and assigns, “**Grantor**”), in favor of the Investors listed on the signature pages hereof.

### RECITALS

A. Grantor and the Investors previously entered into that certain Amended and Restated Intellectual Property Security Agreement, dated as of December 21, 2022 (the “**Prior Agreement**”).

B. Grantor issued (i) secured convertible promissory notes (as amended and restated from time to time, the “**2021 Notes**”) to the Investors pursuant to that certain Secured Convertible Promissory Note Purchase Agreement, dated as of October 27, 2021 (as amended and restated from time to time, the “**2021 Purchase Agreement**”), (ii) secured convertible promissory notes (as amended and restated from time to time, the “**2022 Notes**”), to the Investors pursuant to that certain Secured Convertible Promissory Note Purchase Agreement, dated as of December 21, 2022 (as amended and restated from time to time, the “**2022 Purchase Agreement**”) and (iii) secured convertible promissory notes (as amended and restated from time to time, the “**2023 Notes**”, and together with the 2021 Notes and the 2022 Notes, the “**Notes**”) to the Investors pursuant to that certain Secured Convertible Promissory Note Purchase Agreement, dated as of the date hereof (as amended and restated from time to time, the “**2023 Purchase Agreement**”, and together with the 2021 Purchase Agreement and the 2022 Purchase Agreement, the “**Purchase Agreements**”).

C. Certain of the Investors have agreed to make additional advances of money and to extend certain financial accommodation to Grantor (the “**Loans**”) in the amounts and manner set forth in the 2023 Purchase Agreement. Capitalized terms used herein are used as defined in the 2023 Purchase Agreement. The Investors are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to the Investors (i) a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) and (ii) a security interest in certain collateral of the Company, as set forth in that certain Second Amended and Restated Security Agreement entered into on the date hereof (the “**Security Agreement**”), in each case, to secure the obligations of Grantor under the Notes.

D. Pursuant to the terms of the Security Agreement, Grantor has granted to the Investors a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as defined in the Security Agreement).

E. In order to induce certain Investors to extend the credit evidenced by the 2023 Notes, Company has agreed to enter into this Agreement to amend the Prior Agreement in the form hereof.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Purchase Agreements, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Purchase Agreements, Grantor grants and pledges to the Investors a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and

whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”), provided that the term “Intellectual Property Collateral” shall not include intent-to-use trademark applications until such time as a statement of use is filed with the U.S. Patent and Trademark Office with respect to such intent-to-use trademark application;

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by the Collateral Agent (as defined in the Security Agreement), provided that the Collateral Agent shall not record this agreement against any intent-to-use trademark applications.

3. Authorization. Grantor hereby authorizes the Collateral Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the 2023 Purchase Agreement. The Purchase Agreements are hereby incorporated by reference. The provisions of the Purchase Agreements shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of the Investors with respect to the Intellectual Property Collateral are as provided by the Purchase Agreements, Security Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which

when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Additional Investors. Notwithstanding anything to the contrary contained herein, if the Grantor issues additional Notes after the date hereof, any Investor of such Notes may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed a "Investor" for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as a "Investor" hereunder.

8. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).


9. Prior Agreement. Upon the effectiveness of this Security Agreement, the Prior Agreement shall be deemed amended and restated to read in its entirety as set forth in this Security Agreement

*Signature Pages Follow.*

**IN WITNESS WHEREOF**, the parties have caused this Second Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

**VENTUREMED GROUP, INC.**

DocuSigned by:  
By:   
Name: Denis L. Harrington  
Title: Chief Executive Officer

*[Signature page to Second Amended and Restated Intellectual Property Security Agreement]*

**PATENT**  
**REEL: 065991 FRAME: 0800**

**IN WITNESS WHEREOF**, the parties have caused this Second Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

**ENDEAVOUR MEDTECH GROWTH LP**

By: Endeavour Medtech GP Limited

Its: General Partner

By:  \_\_\_\_\_

Name: Michel Davy

Title: Director

*[Signature page to Second Amended and Restated Intellectual Property Security Agreement]*

**PATENT**  
**REEL: 065991 FRAME: 0801**




**IN WITNESS WHEREOF**, the parties have caused this Second Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

**RIVERVEST VENTURE FUND III, L.P.**

By: RiverVest Venture Partners III, L.P., its  
General Partner

By: RiverVest Venture Partners III, LLC, its  
sole General Partner


DocuSigned by:  
  
By: \_\_\_\_\_  
Name: Karen Spilizewski  
Title: Authorized Person

**RIVERVEST VENTURE FUND III (OHIO),  
L.P.**

By: RiverVest Venture Partners III (Ohio),  
LLC, its General Partner

By: RiverVest Venture Partners III, L.P., its  
sole Member

By: RiverVest Venture Partners III, LLC, its  
sole General Partner

DocuSigned by:  
  
By: \_\_\_\_\_  
Name: Karen Spilizewski  
Title: Authorized Person

*[Signature page to Second Amended and Restated Intellectual Property Security Agreement]*

**PATENT**  
**REEL: 065991 FRAME: 0802**

EXHIBIT A

Copyrights

None

EXHIBIT B

Patents

[see attached]

**VentureMed Group, Inc. Status Report**  
20-Nov-23

US Pending Patent Applications						
Docket No.	Status	Country	Application No.	Application Date	Patent No.	Grant Date
2810-003E	Filed	United States	17/317,999	5/12/2021		
2810-004E	Filed	United States	16/797,585	2/21/2020		
2810-006AA	Filed	United States	17/886,605	8/12/2022		
2810-006BB	Filed	United States	17/886,824	8/12/2022		
2810-006V	Filed	United States	17/728,214	4/25/2022		
2810-006X	Filed	United States	17/221,473	4/2/2021		
2810-006Y	Filed	United States	17/221,539	4/2/2021		
2810-006Z	Filed	United States	17/856,435	7/1/2022		
2810-036	Filed	United States	17/702,336	3/23/2022		
2810-037	Filed	United States	17/702,344	3/23/2022		

US Granted Patents						
Docket No.	Status	Country	Application No.	Application Date	Patent No.	Grant Date
2810-003B	Granted	United States	14/993,478	1/12/2016	11,033,712	6/15/2021
2810-004B	Granted	United States	14/991,493	1/8/2016	10,603,069	3/31/2020
2810-006	Granted	United States	13/613,914	9/13/2012	9,615,848	4/11/2017
2810-006H	Granted	United States	14/990,883	1/8/2016	10,485,570	11/26/2019

2810-006I	Granted	United States	15/481,552	4/7/2017	10,485,572	11/26/2019	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	2nd Maintenance Fee Due 5/26/2027
2810-006J	Granted	United States	15/200,767	7/1/2016	11,413,062	8/16/2022	METHODS FOR PREPARING A ZONE OF ATTENTION WITHIN A VASCULAR SYSTEM FOR SUBSEQUENT ANGIOPLASTY WITH AN INTRAVASCULAR CATHETER DEVICE HAVING AN EXPANDABLE INCISING PORTION AND INTEGRATED EMBOLIC PROTECTION DEVICE	1st Maintenance Fee Due 2/16/2026
2810-006K	Granted	United States	15/368,604	12/3/2016	10,610,255	4/7/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND MEDICATION DELIVERY SYSTEM	2nd Maintenance Fee Due 10/7/2027
2810-006L	Granted	United States	15/441,398	2/24/2017	11,357,533	6/14/2022	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	1st Maintenance Fee Due 12/14/2025
2810-006M	Granted	United States	15/481,562	4/7/2017	11,559,325	1/24/2023	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	1st Maintenance Fee Due 7/24/26
2810-006N	Granted	United States	15/861,955	1/4/2018	10,939,936	3/9/2021	INTRAVASCULAR CATHETER WITH INCISING DEVICES	1st Maintenance Fee Due 9/9/2024
2810-006O	Granted	United States	15/861,969	1/4/2018	10,463,387	11/5/2019	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION FOR INCISING ATHEROSCLEROTIC MATERIAL LOCATED IN A BLOOD VESSEL	2nd Maintenance Fee Due 5/5/2027
2810-006S	Granted	United States	16/673,338	11/4/2019	11,576,698	2/14/2023	INTRAVASCULAR CATHETER DEVICE FOR IMPROVED ANGIOPLASTY	1st Maintenance Fee Due 8/14/2026
2810-006T	Granted	United States	16/693,521	11/25/2019	11,331,118	5/17/2022	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	1st Maintenance Fee Due 11/17/2025
2810-006U	Granted	United States	16/693,520	11/25/2019	11,123,097	9/21/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	1st Maintenance Fee Due 3/21/2025
2810-006W	Granted	United States	16/801,809	2/26/2020	11,571,239	2/7/2023	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND MEDICATION DELIVERY SYSTEM	1st Maintenance Fee Due 8/7/2026
Foreign Pending Patent Applications								
Docket No.	Status	Country	Application No.	Application Date	Patent No.	Grant Date	Title	Next Action Due
2810-006CC	Filed	Australia	2023214268	8/9/2023			INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND EMBOLIC PROTECTION DEVICE	Renewal Fee Due 8/9/2027; Request for Examination Due 8/9/2028

2810-006DD	Filed	China	202311015707.50	8/14/2023		INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND EMBOLIC PROTECTION DEVICE	Request for Examination Due 8/12/2025
2810-006EE	Filed	Europe	23191106.6	8/11/2023		INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND EMBOLIC PROTECTION DEVICE	Renewal Fee Due 8/31/2025
2810-006FF	Filed	Japan	2023-130561	8/11/2023		INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND EMBOLIC PROTECTION DEVICE	Renewal Fee Due 8/10/2026
2810-019C	Filed	Europe	15802872.0	6/3/2015		INTRAVASCULAR CATHETER WITH DRUG DELIVERY SYSTEM	Undergoing Examination; Renewal Fee Due 6/30/2024
2810-036B	Filed	China	202211226214.1	10/9/2022		INTRAVASCULAR DEVICE HAVING FEEDBACK ELEMENTS	Request for Examination Due 3/23/2025
2810-037B	Filed	China	202211238789.5	10/11/2022		INTRAVASCULAR DEVICE FOR TREATING FISTULAS	Request for Examination Due 3/23/2025

Foreign Granted Patents								
Docket No.	Status	Country	Application No.	Application Date	Patent No.	Grant Date	Title	Next Action Due
2810-006R	Granted	Japan	2017-203462	10/20/2017	6752187	8/20/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 8/20/24
2810-003D2	Granted	Italy	16737713.4	1/12/2016	3244815/50202000006670 6	4/22/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE PORTION	Renewal Fee Due 1/31/2024
2810-004D4	Granted	Italy	16737711.8	1/12/2016	3244814/50202100008420 6	7/14/2021	INTRAVASCULAR CATHETER BALLOON DEVICE HAVING A TOOL FOR ATHERECTOMY OR AN INCISING PORTION FOR ATHEROMATOUS PLAQUE	Renewal Fee Due 1/31/2024
2810-006E4	Granted	Italy	12831369.9	9/13/2012	2755714 / 502020000047227	3/11/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/30/2024
2810-006P4	Granted	Italy	18158211.5	2/22/2018	3366239/50202000010755 5	8/12/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	Renewal Fee Due 2/28/2024
2810-006Q3	Granted	Italy	18165683.6	4/4/2018	3384860/50202100002717 6	1/20/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	Renewal Fee Due 4/30/2024
2810-018G	Granted	Italy	15809688.3	6/16/2015	3154454/50202000010400 5	8/5/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND DRUG DELIVERY MECHANISM	Renewal Fee Due 6/30/2024
2810-003D1	Granted	Great Britain	16737713.4	1/12/2016	3244815	4/22/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE PORTION	Renewal Fee Due 1/31/2024

2810-004D6	Granted	Great Britain	16737711.8	1/12/2016	3244814	7/14/2021	INTRAVASCULAR CATHETER BALLOON DEVICE HAVING A TOOL FOR ATHERECTOMY OR AN INCISING PORTION FOR ATHEROMATOUS PLAQUE	Renewal Fee Due 1/31/2024
2810-006E6	Granted	Great Britain	12831369.9	9/13/2012	2755714	3/11/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/30/2024
2810-006P6	Granted	Great Britain	18158211.5	2/22/2018	3366239	8/12/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	Renewal Fee Due 2/28/2024
2810-006Q6	Granted	Great Britain	18165683.6	4/4/2018	3384860	1/20/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	Renewal Fee Due 4/30/2023
2810-018I	Granted	Great Britain	15809688.3	6/16/2015	3154454	8/5/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND DRUG DELIVERY MECHANISM	Renewal Fee Due 6/30/2024
2810-003D3	Granted	France	16737713.4	1/12/2016	3244815	4/22/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE PORTION	Renewal Fee Due 1/31/2024
2810-004D2	Granted	France	16737711.8	1/12/2016	3244814	7/14/2021	INTRAVASCULAR CATHETER BALLOON DEVICE HAVING A TOOL FOR ATHERECTOMY OR AN INCISING PORTION FOR ATHEROMATOUS PLAQUE	Renewal Fee Due 1/31/2024
2810-006E2	Granted	France	12831369.9	9/13/2012	2755714	3/11/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/30/2024
2810-006P2	Granted	France	18158211.5	2/22/2018	3366239	8/12/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	Renewal Fee Due 2/28/2024
2810-006Q4	Granted	France	18165683.6	4/4/2018	3384860	1/20/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	Renewal Fee Due 4/30/2024
2810-018E	Granted	France	15809688.3	6/16/2015	3154454	8/5/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND DRUG DELIVERY MECHANISM	Renewal Fee Due 6/30/2024
2810-004D5	Granted	Spain	16737711.8	1/12/2016	3244814/2892035	7/14/2021	INTRAVASCULAR CATHETER BALLOON DEVICE HAVING A TOOL FOR ATHERECTOMY OR AN INCISING PORTION FOR ATHEROMATOUS PLAQUE	Renewal Fee Due 1/31/2024
2810-006E5	Granted	Spain	12831369.9	9/13/2012	2755714/2791766	3/11/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/30/2024
2810-006P5	Granted	Spain	18158211.5	2/22/2018	3366239/ES 2831026	8/12/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	Renewal Fee Due 2/28/2024

2810-006Q5	Granted	Spain	18165683.6	4/4/2018	3384860/ES 2863779	1/20/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	Renewal Fee Due 4/30/2024
2810-018H	Granted	Spain	15809688.3	6/16/2015	3154454/2828972	8/5/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND DRUG DELIVERY MECHANISM	Renewal Fee Due 6/30/2024
2810-003D	Granted	Europe	16737713.4	1/12/2016	3244815	4/22/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE PORTION	Expiration Date 1/12/2036
2810-004D	Granted	Europe	16737711.8	1/12/2016	3244814	7/14/2021	INTRAVASCULAR CATHETER BALLOON DEVICE HAVING A TOOL FOR ATHERECTOMY OR AN INCISING PORTION FOR ATHEROMATOUS PLAQUE	Expiration Date 1/12/2036
2810-006E	Granted	Europe	12831369.9	9/13/2012	2755714	3/11/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Expiration Date 9/13/2032
2810-006P	Granted	Europe	18158211.5	2/22/2018	3366239	8/12/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	Expiration Date 2/22/2038
2810-006Q	Granted	Europe	18165683.6	4/4/2018	3384860	1/20/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	Expiration Date 4/4/2038
2810-018C	Granted	Europe	15809688.3	6/16/2015	3154454	8/5/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND DRUG DELIVERY MECHANISM	Expiration Date 6/16/2035
2810-003D4	Granted	Germany	16737713.4	1/12/2016	3244815/602016034552.8	4/22/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE PORTION	Renewal Fee Due 1/31/2024
2810-004D3	Granted	Germany	16737711.8	1/12/2016	3244814/602016060596.1	7/14/2021	INTRAVASCULAR CATHETER BALLOON DEVICE HAVING A TOOL FOR ATHERECTOMY OR AN INCISING PORTION FOR ATHEROMATOUS PLAQUE	Renewal Fee Due 1/31/2024
2810-006E3	Granted	Germany	12831369.9	9/13/2012	2755714 / 602012068449.6	3/11/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/30/2024
2810-006P3	Granted	Germany	18158211.5	2/22/2018	3366239/602018006765.5	8/12/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	Renewal Fee Due 2/28/2024
2810-006Q2	Granted	Germany	18165683.6	4/4/2018	3384860/602018011946.9	1/20/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	Renewal Fee Due 4/30/2024
2810-018F	Granted	Germany	15809688.3	6/16/2015	3154454/602015057051.0	8/5/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND DRUG DELIVERY MECHANISM	Renewal Fee Due 6/30/2024
2810-006G	Granted	China	201280050299.0	9/13/2012	ZL 201280050299.0	6/23/2017	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/13/2024



2810-006F	Granted	Brazil	BR 112014005721-4	9/13/2012	BR 112014005721-4	12/29/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/13/2024
2810-006C	Granted	Australia	2012308610	9/13/2012	2012308610	6/22/2017	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/13/2024
2810-004D1	Granted	Austria	16737711.8	1/12/2016	3244814 / AT E 1410038	7/14/2021	INTRAVASCULAR CATHETER BALLOON DEVICE HAVING A TOOL FOR ATHERECTOMY OR AN INCISING PORTION FOR ATHEROMATOUS PLAQUE	Renewal Fee Due 1/31/2024
2810-006E1	Granted	Austria	12831369.9	9/13/2012	2755714 / AT E1242175	3/11/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION	Renewal Fee Due 9/30/2024
2810-006P1	Granted	Austria	18158211.5	2/22/2018	3366239	8/12/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND ABRASIVE SURFACES	Renewal Fee Due 2/28/2024
2810-006Q1	Granted	Austria	18165683.6	4/4/2018	3384860/AT E1355667	1/20/2021	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND GRATING TOOL	Renewal Fee Due 4/30/2024
2810-018D	Granted	Austria	15809688.3	6/16/2015	3154454 / E 1297612	8/5/2020	INTRAVASCULAR CATHETER HAVING AN EXPANDABLE INCISING PORTION AND DRUG DELIVERY MECHANISM	Renewal Fee Due 6/30/2024

EXHIBIT C

Trademarks

[see attached]






PRIVILEGED AND CONFIDENTIAL VentureMed Trademark Status Report Current as of November 2023							
SLG Reference	Status	Country / Region	Application Number	Application Date	Registration Number	Registration Date	Mark
2810-005B	Registered - (G)	US - (United States)	86/956,879	3/29/2016	5,106,824	12/20/2016	DYNAMIC SCORING
2810-007	Registered - (G)	US - (United States)	86/387,866	9/8/2014	4,978,767	6/14/2016	VENTUREMED
2810-008	Registered - (G)	US - (United States)	86/387,867	9/8/2014	5,464,821	5/8/2018	VMG
2810-012	Registered - (G)	US - (United States)	86/387,875		4,978,768		
2810-013	Registered - (G)	US - (United States)	86/387,876	9/8/2014	4,969,505	6/14/2016	
2810-030B	Registered - (G)	US - (United States)	88/891,749	9/8/2014		5/31/2016	
2810-031	Registered - (G)	US - (United States)	88/267,596	4/28/2020	6,457,925	8/17/2021	FLEX VESSEL PREP
2810-032	Registered - (G)	US - (United States)	88/411,102	1/18/2019	6,694,572	4/5/2022	FLEX VP
2810-032C	Registered - (G)	BR - (Brazil)	917774710	5/1/2019		2/9/2021	
2810-032D	Registered - (G)	IB - (Australia, China, Switzerland, EU, Japan, UK)	A0090496	7/19/2019	917774710	3/17/2020	
2810-038	Registered - (G)	US - (United States)	97/424,024	10/9/2019		10/9/2019	
2810-038B	Registered - (G)	EM - (European Union)	018762040	5/23/2022	7,098,853	7/4/2023	
2810-038C	Registered - (G)	CH - (Switzerland)	12382/2022	9/15/2022	018762040	1/13/2023	
2810-038D	Registered - (G)	GB - (Great Britain)	UK00003829830	9/15/2022	UK00003829830	2/17/2023	

EXHIBIT D

Mask Works

None